---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-140152"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:48:12.456102+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO

## Summary
- Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.
- Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.
- Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.
- Levine's vested options exercisable for 12 months after separation date.
- Erlander resigns from board of directors effective March 27, 2026.

## SEC filing metadata
- accession: 0001193125-26-140152
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/0001193125-26-140152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/crdf-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-140152
- JSON: https://secwatch.observer/filing/0001193125-26-140152.json
- Plain text: https://secwatch.observer/filing/0001193125-26-140152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.